Oral epigallocatechin-3-gallate for treatment of dystrophic epidermolysis bullosa: a multicentre, randomized, crossover, double-blind, placebo-controlled clinical trial | Orphanet Journal of Rare Diseases | Full Text

Oral epigallocatechin-3-gallate for treatment of dystrophic epidermolysis bullosa: a multicentre, randomized, crossover, double-blind, placebo-controlled clinical trial | Orphanet Journal of Rare Diseases | Full Text

The following new article has just been published in Orphanet Journal of Rare Diseases

Letter to the Editor   Oral epigallocatechin-3-gallate for treatment of dystrophic epidermolysis bullosa: a multicentre, randomized, crossover, double-blind, placebo-controlled clinical trial Chiaverini C, Roger C, Fontas E, Bourrat E, Bourdon-Lanoy E, Labrèze C, Mazereeuw J, Vabres P, Bodemer C, Lacour JOrphanet Journal of Rare Diseases 2016, 11 :31 (25 March 2016) Abstract | Full Text | PDF